Skocz do pozycji: 1.

Tytuł:

Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease.

Autorzy:

Marmor M; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America. .
Sharifi H; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Jacobs S; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Fazeli K; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Ruoss S; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.

Pokaż więcej

Źródło:

Respiratory research [Respir Res] 2024 Mar 11; Vol. 25 (1), pp. 123. Date of Electronic Publication: 2024 Mar 11.

Typ publikacji:

Review; Journal Article

MeSH Terms:

Mycobacterium avium-intracellulare Infection*/diagnosis
Mycobacterium avium-intracellulare Infection*/drug therapy
Mycobacterium avium-intracellulare Infection*/microbiology
Lung Diseases*/diagnosis
Lung Diseases*/drug therapy
Lung Diseases*/epidemiology
Liver Diseases*
Humans ; Mycobacterium avium Complex ; Retrospective Studies ; Drug Therapy, Combination ; Anti-Bacterial Agents/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 2.

Tytuł:

The prevalence, clinical reasoning and impact of non-standard anti-tuberculosis regimens at the initial prescription.

Autorzy:

Chen RT; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
Liu CY; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
Lin SY; College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, No 7, Chung Shan South Road, Taipei, Taiwan.
Shu CC; College of Medicine, National Taiwan University, Taipei, Taiwan. .; Department of Internal Medicine, National Taiwan University Hospital, No 7, Chung Shan South Road, Taipei, Taiwan. .
Sheng WH; College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, No 7, Chung Shan South Road, Taipei, Taiwan.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Mar 07; Vol. 14 (1), pp. 5631. Date of Electronic Publication: 2024 Mar 07.

Typ publikacji:

Journal Article

MeSH Terms:

Tuberculosis*/drug therapy
Tuberculosis*/epidemiology
Tuberculosis, Multidrug-Resistant*/drug therapy
Gout*/drug therapy
Humans ; Antitubercular Agents/therapeutic use ; Prevalence ; Drug Therapy, Combination ; Clinical Reasoning

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 3.

Tytuł:

Clopidogrel with indobufen or aspirin in minor ischemic stroke or high-risk transient ischemic attack: a randomized controlled clinical study.

Autorzy:

Liu X; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Lv X; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Peng Y; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Wang J; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Lei J; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Tang C; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Luo S; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Mai W; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Cai Y; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Fan Q; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Liu C; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Zhang L; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China. .

Pokaż więcej

Źródło:

BMC neurology [BMC Neurol] 2024 Mar 01; Vol. 24 (1), pp. 81. Date of Electronic Publication: 2024 Mar 01.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Ischemic Attack, Transient*/drug therapy
Ischemic Attack, Transient*/epidemiology
Ischemic Stroke*/drug therapy
Stroke*/drug therapy
Phenylbutyrates*
Isoindoles*
Humans ; Aspirin ; Clopidogrel/therapeutic use ; Platelet Aggregation Inhibitors/adverse effects ; Prospective Studies ; Hemorrhage/chemically induced ; Drug Therapy, Combination ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 4.

Tytuł:

Efficacy and tolerability of adjunctive lacosamide in patients aged <4 years with focal seizures.

Autorzy:

Makedonska I; Municipal Non-profit Enterprise City Children's Clinical Hospital #6 of Dnipro City Council, Dnipro, Ukraine.
Ng YT; Baylor College of Medicine/The Children's Hospital of San Antonio, San Antonio, Texas, USA.
Beller C; UCB Pharma, Morrisville, North Carolina, USA.
Bozorg A; UCB Pharma, Morrisville, North Carolina, USA.
Csikós J; UCB Pharma, Monheim am Rhein, Germany.
McClung C; UCB Pharma, Morrisville, North Carolina, USA.
Moeltgen H; UCB Pharma, Monheim am Rhein, Germany.
Farkas MK; Pediatric Center, MTA Center of Excellence, Semmelweis University, Budapest, Hungary.

Pokaż więcej

Corporate Authors:

SP0967 Study Group

Źródło:

Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2024 Mar; Vol. 11 (3), pp. 768-779. Date of Electronic Publication: 2024 Feb 20.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Anticonvulsants*/adverse effects
Epilepsies, Partial*/drug therapy
Adult ; Child ; Humans ; Child, Preschool ; Lacosamide/adverse effects ; Reproducibility of Results ; Acetamides/adverse effects ; Drug Therapy, Combination ; Dose-Response Relationship, Drug ; Treatment Outcome ; Seizures/drug therapy ; Seizures/chemically induced

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 5.

Tytuł:

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.

Autorzy:

Semitala FC; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.; Makerere University Joint AIDS Program, Kampala Uganda.
Kadota JL; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Musinguzi A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Welishe F; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakitende A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Akello L; Infectious Diseases Research Collaboration, Kampala, Uganda.
Kunihira Tinka L; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakimuli J; Infectious Diseases Research Collaboration, Kampala, Uganda.
Ritar Kasidi J; Infectious Diseases Research Collaboration, Kampala, Uganda.
Bishop O; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakasendwa S; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
Baik Y; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Patel D; The Better Lab and Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Sammann A; The Better Lab and Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Nahid P; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Belknap R; Denver Health and Hospital Authority and Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado, United States of America.
Kamya MR; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.
Handley MA; Center for Vulnerable Populations, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Phillips PP; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Katahoire A; Child Health and Development Center, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Berger CA; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Kiwanuka N; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
Katamba A; Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
Dowdy DW; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Cattamanchi A; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.; Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Irvine, California, United States of America.

Pokaż więcej

Źródło:

PLoS medicine [PLoS Med] 2024 Feb 20; Vol. 21 (2), pp. e1004356. Date of Electronic Publication: 2024 Feb 20 (Print Publication: 2024).

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Tuberculosis*/drug therapy
Tuberculosis*/prevention & control
Latent Tuberculosis*/drug therapy
HIV Infections*/complications
HIV Infections*/drug therapy
Rifampin/*analogs & derivatives
Humans ; Isoniazid/adverse effects ; Antitubercular Agents/adverse effects ; Uganda ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 6.

Tytuł:

Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy.

Autorzy:

Sun J; Department of Orthopaedics, The First Affiliated Hospital of Jishou University, The People's Hospital of Xiangxi Autonomous Prefecture, Jishou, China.
Zhang C; Department of Jishou University, Jishou, China.
Su X; Department of Jishou University, Jishou, China.
Zhou H; Department of Medicine, Taizhou University, Zhejiang, China.
Zhou S; Department of Medicine, Taizhou University, Zhejiang, China.
Jiang M; Department of Medicine, Taizhou University, Zhejiang, China.
Fang B; Department of Medicine, Taizhou University, Zhejiang, China. .

Pokaż więcej

Źródło:

Journal of orthopaedic surgery and research [J Orthop Surg Res] 2024 Feb 19; Vol. 19 (1), pp. 147. Date of Electronic Publication: 2024 Feb 19.

Typ publikacji:

Journal Article

MeSH Terms:

Hypertension*/drug therapy
Fibrosarcoma*/drug therapy
Humans ; Antihypertensive Agents/therapeutic use ; Losartan/pharmacology ; Losartan/therapeutic use ; Captopril/pharmacology ; Captopril/therapeutic use ; Spironolactone/therapeutic use ; Furosemide/therapeutic use ; CD8-Positive T-Lymphocytes ; Hydrochlorothiazide/therapeutic use ; Drug Therapy, Combination ; Verapamil/pharmacology ; Verapamil/therapeutic use ; Solute Carrier Family 12, Member 3

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 7.

Tytuł:

Association between failed eradication of 7-day triple therapy for Helicobacter pylori and untreated dental caries in Japanese adults.

Autorzy:

Iwai K; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Azuma T; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Yonenaga T; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Sasai Y; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Watanabe K; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Obora A; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Deguchi F; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Kojima T; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Tomofuji T; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Feb 19; Vol. 14 (1), pp. 4043. Date of Electronic Publication: 2024 Feb 19.

Typ publikacji:

Journal Article

MeSH Terms:

Helicobacter pylori*
Dental Caries*/drug therapy
Helicobacter Infections*/complications
Helicobacter Infections*/drug therapy
Anti-Infective Agents*/therapeutic use
Adult ; Humans ; Anti-Bacterial Agents/therapeutic use ; Cross-Sectional Studies ; Japan/epidemiology ; Drug Therapy, Combination ; Treatment Outcome ; Clarithromycin/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 8.

Tytuł:

Exploring the Roles of Vitamins C and D and Etifoxine in Combination with Citalopram in Depression/Anxiety Model: A Focus on ICAM-1, SIRT1 and Nitric Oxide.

Autorzy:

Gammoh O; Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
Ibrahim A; Faculty of Sciences, Yarmouk University, Irbid 21163, Jordan.
Yehya A; Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
Alqudah A; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan.
Qnais E; Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa 13133, Jordan.
Altaber S; Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa 13133, Jordan.
Alrob OA; Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
Aljabali AAA; Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan.
Tambuwala MM; Lincoln Medical School, Brayford Pool Campus, University of Lincoln, Lincoln LN6 7TS, UK.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2024 Feb 06; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 06.

Typ publikacji:

Journal Article

MeSH Terms:

Anxiety*/drug therapy
Citalopram*/pharmacology
Citalopram*/therapeutic use
Depression*/drug therapy
Nitric Oxide*
Oxazines*/pharmacology
Oxazines*/therapeutic use
Animals ; Mice ; Antidepressive Agents/pharmacology ; Antidepressive Agents/therapeutic use ; Ascorbic Acid/pharmacology ; Ascorbic Acid/therapeutic use ; Intercellular Adhesion Molecule-1 ; Sirtuin 1 ; Vitamin D/pharmacology ; Vitamin D/therapeutic use ; Vitamins ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 9.

Tytuł:

Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry.

Autorzy:

Dai C; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Liu M; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Yang Z; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Li Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Zhou Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Lu D; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Xia Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Chen A; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Li C; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Lu H; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Dai Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Ma J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Chen Z; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China. .; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .
Qian J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China. .; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .
Ge J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China. .; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .

Pokaż więcej

Źródło:

BMC medicine [BMC Med] 2024 Apr 02; Vol. 22 (1), pp. 148. Date of Electronic Publication: 2024 Apr 02.

Typ publikacji:

Clinical Trial; Journal Article

MeSH Terms:

Acute Coronary Syndrome*/drug therapy
Acute Coronary Syndrome*/surgery
Isoindoles*
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/methods
Phenylbutyrates*
Humans ; Aspirin/adverse effects ; Drug Therapy, Combination ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Platelet Aggregation Inhibitors/adverse effects ; Registries ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 10.

Tytuł:

Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.

Autorzy:

Lim SY; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lee J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Osuna CE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Vikhe P; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Schalk DR; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Chen E; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Fray E; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Kumar M; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Schultz-Darken N; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Rakasz E; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Capuano S; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Ladd RA; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Gil HM; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Evans DT; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Jeng EK; Altor Biosciences, Miramar, FL 33027, USA.
Seaman M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Martin M; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Van Dorp C; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Perelson AS; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.; Santa Fe Institute, Santa Fe, NM 87501, USA.
Wong HC; Altor Biosciences, Miramar, FL 33027, USA.
Siliciano JD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Siliciano R; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Safrit JT; ImmunityBio, Culver City, CA 90232, USA.
Nixon DF; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Soon-Shiong P; ImmunityBio, Culver City, CA 90232, USA.
Nussenzweig M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.
Whitney JB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.; Department of Biology, Boston College, Chestnut Hill, MA 02467, USA.

Pokaż więcej

Źródło:

Science (New York, N.Y.) [Science] 2024 Mar 08; Vol. 383 (6687), pp. 1104-1111. Date of Electronic Publication: 2024 Feb 29.

Typ publikacji:

Journal Article

MeSH Terms:

Anti-Retroviral Agents*/therapeutic use
Anti-Retroviral Agents*/pharmacology
Simian Acquired Immunodeficiency Syndrome*/drug therapy
Simian Acquired Immunodeficiency Syndrome*/therapy
Simian Immunodeficiency Virus*
Recombinant Fusion Proteins*/administration & dosage
Recombinant Fusion Proteins*/pharmacology
Animals ; Humans ; Broadly Neutralizing Antibodies/administration & dosage ; CD8-Positive T-Lymphocytes/virology ; Immunotherapy ; Macaca mulatta ; Viral Load ; Remission Induction ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 11.

Tytuł:

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes.

Autorzy:

Ali RA; Zoology Department, Faculty of Science, South Valley University, Qena, Egypt.
Awadalla EA; Zoology Department, Faculty of Science, Aswan University, Aswan, Egypt.
Amin YA; Department of Theriogenology, Faculty of Veterinary Medicine, Aswan University, Aswan, Egypt. .
Fouad SS; Qena University Hospital, South Valley University, Qena, Egypt.
Ahmed MAB; Department of Anatomy, Faculty of Medicine, South Valley University, Qena, Egypt.
Hassan MH; Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt.
Abdel-Kahaar E; Department of Medical Pharmacology, Faculty of Medicine, South Valley University, Qena, Egypt.; Institute of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg, Germany.
Abdel-Aziz RH; Department of Medical Physiology, Faculty of Medicine, South Valley University, Qena, Egypt.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Mar 07; Vol. 14 (1), pp. 5682. Date of Electronic Publication: 2024 Mar 07.

Typ publikacji:

Journal Article

MeSH Terms:

Hepatitis C, Chronic*/drug therapy
Pancreatitis*/chemically induced
Humans ; Adult ; Child ; Male ; Animals ; Rats ; Antiviral Agents/adverse effects ; Sofosbuvir/adverse effects ; Ribavirin/therapeutic use ; Hepacivirus/genetics ; Acute Disease ; Treatment Outcome ; Drug Therapy, Combination ; Semen ; Sperm Motility ; Liver Cirrhosis/complications ; Lipase/genetics ; Genotype

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 12.

Tytuł:

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies.

Autorzy:

Underwood M; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Urbaityte R; GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Wang R; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Horton J; Parexel, 2520 Meridian Parkway, Durham, NC 27713, USA.
Oyee J; GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Wynne B; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Fox D; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Jones B; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Man C; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Sievers J; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.

Pokaż więcej

Źródło:

Viruses [Viruses] 2024 Mar 06; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 06.

Typ publikacji:

Journal Article

MeSH Terms:

HIV Infections*/drug therapy
Anti-HIV Agents*/therapeutic use
HIV-1*
HIV Seropositivity*
Oxazines*
Piperazines*
Pyridones*
Adult ; Humans ; Lamivudine/therapeutic use ; Emtricitabine/therapeutic use ; Tenofovir/therapeutic use ; Drug Therapy, Combination ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Viral Load ; Virus Replication

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 13.

Tytuł:

Clinical outcomes and risk factors for immune recovery and all-cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study.

Autorzy:

Castillo-Rozas G; Laboratory of Molecular and Cellular Virology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.; HIV/AIDS Workgroup, Faculty of Medicine, University of Chile, Santiago, Chile.
Tu S; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Luz PM; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Mejia F; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú.
Sierra-Madero J; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
Rouzier V; Groupe Haitien d'Etudes du Sarcome de Kaposi et des Infections Opportunistes, Port-au-Prince, Haiti.
Shepherd BE; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Cortes CP; HIV/AIDS Workgroup, Faculty of Medicine, University of Chile, Santiago, Chile.; Department of Internal Medicine, Faculty of Medicine, University of Chile, Santiago, Chile.; Hospital Clínico San Borja Arriarán & Fundación Arriarán, Santiago, Chile.; Millenium Institute on Immunology and Immunotherapy, Santiago, Chile.

Pokaż więcej

Źródło:

Journal of the International AIDS Society [J Int AIDS Soc] 2024 Mar; Vol. 27 (3), pp. e26214.

Typ publikacji:

Journal Article

MeSH Terms:

HIV Infections*
Acquired Immunodeficiency Syndrome*/drug therapy
Anti-HIV Agents*/therapeutic use
Humans ; Male ; Retrospective Studies ; Risk Factors ; Drug Therapy, Combination ; CD4 Lymphocyte Count ; Viral Load ; Antiretroviral Therapy, Highly Active

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 14.

Tytuł:

Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

Autorzy:

Kishi T; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Sakuma K; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Hatano M; Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Matsuda Y; Department of Psychiatry, Jikei University School of Medicine, Minato, Tokyo, Japan.
Esumi S; Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Hyogo, Japan.
Miyake N; Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Miura I; Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hori H; Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Kato M; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Iwata N; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.

Pokaż więcej

Źródło:

Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 216-220. Date of Electronic Publication: 2023 Aug 30.

Typ publikacji:

Meta-Analysis; Systematic Review; Journal Article

MeSH Terms:

Depressive Disorder, Major*/drug therapy
Adult ; Humans ; Japan ; Antidepressive Agents/therapeutic use ; Drug Therapy, Combination ; Randomized Controlled Trials as Topic

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 15.

Tytuł:

Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.

Autorzy:

Zandifar A; Social Determinants of Health Research Center, Alborz University of Medical Sciences, Karaj, Iran.; Department of Psychiatry, Imam Hossein Hospital, Alborz University of Medical Sciences, Karaj, Alborz, Iran.
Panahi M; Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Badrfam R; Department of Psychiatry, Imam Hossein Hospital, Alborz University of Medical Sciences, Karaj, Alborz, Iran. .
Qorbani M; Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.; Chronic Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Pokaż więcej

Źródło:

BMC psychiatry [BMC Psychiatry] 2024 Feb 26; Vol. 24 (1), pp. 163. Date of Electronic Publication: 2024 Feb 26.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Benzhydryl Compounds*
Citalopram*/therapeutic use
Depressive Disorder, Major*/drug therapy
Glucosides*
Humans ; Antidepressive Agents/therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Treatment Outcome ; Adolescent ; Young Adult ; Adult ; Middle Aged

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 16.

Tytuł:

COVID vaccine-induced lupus nephritis: Case report and review of the literature.

Autorzy:

Salas A; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fatola A; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Krimins R; Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kamel IR; Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Geetha D; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fine D; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Monroy-Trujillo M; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rosenberg A; Division of Kidney-Urologic Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Arend L; Division of Kidney-Urologic Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Timlin H; Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA.

Pokaż więcej

Źródło:

Lupus [Lupus] 2024 Feb; Vol. 33 (2), pp. 176-182. Date of Electronic Publication: 2024 Jan 02.

Typ publikacji:

Review; Case Reports; Journal Article

MeSH Terms:

Lupus Nephritis*/drug therapy
COVID-19*
Lupus Erythematosus, Systemic*/chemically induced
Vaccines*
Humans ; Female ; Immunosuppressive Agents/therapeutic use ; COVID-19 Vaccines ; Drug Therapy, Combination ; Mycophenolic Acid/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 17.

Tytuł:

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.

Autorzy:

Moon JS; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Park IR; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Kim SS; Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Kim HS; Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Kim NH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul.
Kim SG; Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul.
Ko SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Lee JH; Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Lee I; Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
Lee BK; Clinical Operation Team, Yuhan Corporation, Seoul, Korea.
Won KC; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.

Pokaż więcej

Źródło:

Diabetes & metabolism journal [Diabetes Metab J] 2023 Nov; Vol. 47 (6), pp. 818-825. Date of Electronic Publication: 2023 Nov 24.

Typ publikacji:

Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; Journal Article

MeSH Terms:

Anticholesteremic Agents*/adverse effects
Hypercholesterolemia*
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Cardiovascular Diseases*/epidemiology
Cardiovascular Diseases*/etiology
Cardiovascular Diseases*/prevention & control
Atherosclerosis*/drug therapy
Atherosclerosis*/epidemiology
Humans ; Rosuvastatin Calcium/adverse effects ; Ezetimibe/adverse effects ; Cholesterol, LDL ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 18.

Tytuł:

Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.

Autorzy:

Dawson R; Division of Pulmonology, Department of Medicine, University of Cape Town and University of Cape Town Lung Institute, Cape Town, South Africa.
Diacon AH; Department of Medicine, Stellenbosch University, Cape Town, South Africa.; TASK Applied Science, Cape Town, South Africa.
Takuva S; Otsuka Novel Products GmbH, Munich, Germany.; Faculty of Health Sciences, School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa.
Liu Y; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.
Zheng B; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.
Karwe V; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.
Hafkin J; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA. .

Pokaż więcej

Źródło:

Trials [Trials] 2024 Jan 19; Vol. 25 (1), pp. 70. Date of Electronic Publication: 2024 Jan 19.

Typ publikacji:

Clinical Trial Protocol; Journal Article

MeSH Terms:

Diarylquinolines*
HIV Infections*/drug therapy
Nitroimidazoles*
Oxazoles*
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Pulmonary*/diagnosis
Tuberculosis, Pulmonary*/drug therapy
Tuberculosis, Pulmonary*/microbiology
Humans ; Antitubercular Agents ; Clinical Trials, Phase II as Topic ; Drug Therapy, Combination ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 19.

Tytuł:

The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials.

Autorzy:

Liu LH; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China. .
Han B; Department of Endoscopy, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China.
Tao J; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China.
Zhang K; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China.
Wang XK; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China.
Wang WY; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, 395 Jinzhu East Road, Guanshanhu District, Guiyang City, Guizhou Province, China. .

Pokaż więcej

Źródło:

BMC infectious diseases [BMC Infect Dis] 2023 Dec 15; Vol. 23 (1), pp. 878. Date of Electronic Publication: 2023 Dec 15.

Typ publikacji:

Meta-Analysis; Systematic Review; Journal Article

MeSH Terms:

Saccharomyces boulardii*
Helicobacter pylori*
Helicobacter Infections*/drug therapy
Helicobacter Infections*/prevention & control
Probiotics*/therapeutic use
Child ; Humans ; Drug Therapy, Combination ; Randomized Controlled Trials as Topic ; Abdominal Pain/drug therapy ; Dietary Supplements ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 20.

Tytuł:

Tailoring antiplatelet therapy in older patients with coronary artery disease.

Autorzy:

Kovacevic M; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Pompei G; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK and.
Kunadian V; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK and.; Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Pokaż więcej

Źródło:

Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2285446. Date of Electronic Publication: 2023 Dec 05.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Coronary Artery Disease*/complications
Percutaneous Coronary Intervention*/adverse effects
Acute Coronary Syndrome*/drug therapy
Humans ; Aged ; Platelet Aggregation Inhibitors/adverse effects ; Aspirin/therapeutic use ; Dual Anti-Platelet Therapy/methods ; Hemorrhage/drug therapy ; Drug Therapy, Combination ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 21.

Tytuł:

Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial.

Autorzy:

Alavian G; Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Abbasian L; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. .; Department of Infectious & Tropical Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Keshavarz Blvd, Tehran, Iran. .
Khalili H; Department of Clinical Pharmacy (Pharmacotherapy), Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Alinaghi SAS; Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Hasannezhad M; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Ashtiani MF; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Manshadi SAD; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.

Pokaż więcej

Źródło:

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences [Daru] 2023 Dec; Vol. 31 (2), pp. 145-153. Date of Electronic Publication: 2023 Aug 04.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

HIV Infections*/drug therapy
Drug-Related Side Effects and Adverse Reactions*/drug therapy
Anti-HIV Agents*/therapeutic use
Anti-HIV Agents*/adverse effects
Humans ; Tenofovir/adverse effects ; Emtricitabine/adverse effects ; Pilot Projects ; Treatment Outcome ; Adenine ; Drug Therapy, Combination ; RNA/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 22.

Tytuł:

Mycophenolate mofetil as a treatment for presumed idiopathic chronic hepatitis in dogs: Six cases (2010-2022).

Autorzy:

Beehler MK; Department of Internal Medicine, Angell Animal Medical Center, Boston, Massachusetts, USA.
Kearns SA; Department of Internal Medicine, Angell Animal Medical Center, Boston, Massachusetts, USA.
Crouse ZJ; Department of Internal Medicine, Angell Animal Medical Center, Boston, Massachusetts, USA.

Pokaż więcej

Źródło:

Veterinary medicine and science [Vet Med Sci] 2023 Nov; Vol. 9 (6), pp. 2527-2533. Date of Electronic Publication: 2023 Sep 02.

Typ publikacji:

Journal Article

MeSH Terms:

Mycophenolic Acid*/adverse effects
Dog Diseases*/drug therapy
Dog Diseases*/chemically induced
Dogs ; Animals ; Prednisone ; Immunosuppressive Agents/therapeutic use ; Retrospective Studies ; Drug Therapy, Combination/veterinary ; Hepatitis, Chronic/drug therapy ; Hepatitis, Chronic/veterinary

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 23.

Tytuł:

Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension.

Autorzy:

Moon JS; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Park IR; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Kim HJ; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
Chung CH; Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.
Won KC; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Han KA; Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
Park CY; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Won JC; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.
Kim DJ; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
Koh GP; Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Korea.
Kim ES; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Yu JM; Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea.
Hong EG; Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
Lee CB; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Yoon KH; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Pokaż więcej

Źródło:

Diabetes & metabolism journal [Diabetes Metab J] 2023 Nov; Vol. 47 (6), pp. 808-817. Date of Electronic Publication: 2023 Sep 26.

Typ publikacji:

Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article

MeSH Terms:

Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/chemically induced
Metformin*/adverse effects
Humans ; Hypoglycemic Agents/adverse effects ; Glycated Hemoglobin ; Drug Therapy, Combination ; Glucose

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 24.

Tytuł:

Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy.

Autorzy:

de Araujo ACGDS; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (INI/Fiocruz), Rio de Janeiro, RJ, Brazil.
Hacker MAV; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
Pinheiro RO; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
Illarramendi X; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
Durães SMB; Dermatology Department, Fluminense Federal University (UFF), Niterói, RJ, Brazil.
Nobre ML; Giselda Trigueiro Hospital, Rio Grande do Norte Federal State Public Health department (SESAP-RN), Natal, RN, Brazil.
Moraes MO; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
Sales AM; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
da Silva GMS; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (INI/Fiocruz), Rio de Janeiro, RJ, Brazil.

Pokaż więcej

Źródło:

PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2024 Jan 25; Vol. 18 (1), pp. e0011901. Date of Electronic Publication: 2024 Jan 25 (Print Publication: 2024).

Typ publikacji:

Journal Article

MeSH Terms:

Leprosy*/drug therapy
Drug-Related Side Effects and Adverse Reactions*
Adult ; Humans ; Female ; Dapsone/adverse effects ; Leprostatic Agents/adverse effects ; Rifampin/therapeutic use ; Drug Therapy, Combination ; Case-Control Studies ; Clofazimine/therapeutic use ; Brazil/epidemiology ; World Health Organization

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 25.

Tytuł:

Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts.

Autorzy:

Kokori E; Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara, Nigeria.
Olatunji G; Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara, Nigeria.
Akinboade A; Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara, Nigeria.
Akinoso A; Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara, Nigeria.
Egbunu E; Federal Medical Centre, Bida, Niger, Nigeria.
Aremu SA; Lagos University Teaching Hospital, Lagos, Nigeria.
Okafor CE; Afe Babalola University, Ado Ekiti, Nigeria.
Oluwole O; Lagos University Teaching Hospital, Lagos, Nigeria.
Aderinto N; Department of Medicine, Ladoke Akintola University of Technology, Ogbomosho, Nigeria. .

Pokaż więcej

Źródło:

Malaria journal [Malar J] 2024 Jan 18; Vol. 23 (1), pp. 25. Date of Electronic Publication: 2024 Jan 18.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Antimalarials*/therapeutic use
Malaria*/drug therapy
Malaria*/prevention & control
Artemisinins*/therapeutic use
Humans ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 26.

Tytuł:

Efficacy of a 2-week therapy with levofloxacin concomitant versus a levofloxacin sequential regimen for Helicobacter pylori infection in the Syrian population: a study protocol for randomized controlled trial.

Autorzy:

Alhalabi M; Gastroenterology Department, Damascus Hospital, Almujtahed Street, Damascus, Syria. .
Almokdad R; Gastroenterology Department, Damascus Hospital, Almujtahed Street, Damascus, Syria.

Pokaż więcej

Źródło:

Trials [Trials] 2024 Jan 15; Vol. 25 (1), pp. 55. Date of Electronic Publication: 2024 Jan 15.

Typ publikacji:

Clinical Trial Protocol; Journal Article

MeSH Terms:

Helicobacter Infections*/diagnosis
Helicobacter Infections*/drug therapy
Helicobacter pylori*
Adolescent ; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Anti-Bacterial Agents/adverse effects ; Clinical Protocols ; Drug Therapy, Combination ; Levofloxacin/adverse effects ; Metronidazole ; Prospective Studies ; Proton Pump Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Syria ; Treatment Outcome ; Equivalence Trials as Topic

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 27.

Tytuł:

A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study).

Autorzy:

Kim HJ; Department of Endocrinology & Metabolism, Ajou University School of Medicine, Suwon, Republic of Korea.
Noh JH; Division of Endocrinology and Metabolism, Department of Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea.
Moon MK; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
Choi SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Ko SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Rhee EJ; Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Hur KY; Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jeong IK; Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Republic of Korea.

Pokaż więcej

Źródło:

Journal of diabetes research [J Diabetes Res] 2024 Jan 05; Vol. 2024, pp. 8915591. Date of Electronic Publication: 2024 Jan 05 (Print Publication: 2024).

Typ publikacji:

Randomized Controlled Trial; Multicenter Study; Journal Article

MeSH Terms:

Diabetes Mellitus, Type 2*/drug therapy
Metformin*/administration & dosage
Piperidones*
Pyrimidines*
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Humans ; Blood Glucose ; Double-Blind Method ; Drug Therapy, Combination ; Glycated Hemoglobin ; Glycemic Control ; Hypoglycemic Agents/administration & dosage ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 28.

Tytuł:

Factors influencing patients' adherence to malaria artemisinin-based combination therapy in Kamuli District, Uganda.

Autorzy:

Bawate C; Kamuli General Hospital-Kamuli District Local Government, Kamuli, Uganda. .
Callender-Carter ST; Bugema University, Kampala, Uganda.
Guyah B; School of Public Health and Community Development, Maseno University, Maseno, Kenya.
Ouma C; School of Public Health and Community Development, Maseno University, Maseno, Kenya.

Pokaż więcej

Źródło:

Malaria journal [Malar J] 2024 Jan 02; Vol. 23 (1), pp. 1. Date of Electronic Publication: 2024 Jan 02.

Typ publikacji:

Journal Article

MeSH Terms:

Artemisinins*/therapeutic use
Malaria*/drug therapy
Malaria*/prevention & control
Malaria*/epidemiology
Antimalarials*/therapeutic use
Female ; Humans ; Young Adult ; Adult ; Male ; Uganda ; Longitudinal Studies ; Drug Combinations ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 29.

Tytuł:

Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases.

Autorzy:

Welzel T; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland. .; Division of Pediatric Rheumatology, Department of Pediatrics and Autoinflammation Reference Centre Tuebingen (arcT), University Hospital Tuebingen, Tuebingen, Germany. .; Pediatric Rheumatology, University Children's Hospital Basel, University of Basel, Basel, Switzerland. .; Pediatric Research Center, University Children's Hospital Basel, University of Basel, Basel, Switzerland. .
Golhen K; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Atkinson A; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.; Pediatric Research Center, University Children's Hospital Basel, University of Basel, Basel, Switzerland.; Division of Infectious Diseases, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Gotta V; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Ternant D; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.; Université de Tours, service de pharmacologie médicale, Tours France, Université de Tours, EA 4245 T2I, Tours, France.
Kuemmerle-Deschner JB; Division of Pediatric Rheumatology, Department of Pediatrics and Autoinflammation Reference Centre Tuebingen (arcT), University Hospital Tuebingen, Tuebingen, Germany.
Michler C; Division of Pediatric Rheumatology, Department of Pediatrics and Autoinflammation Reference Centre Tuebingen (arcT), University Hospital Tuebingen, Tuebingen, Germany.
Koch G; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
van den Anker JN; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Pfister M; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Woerner A; Pediatric Rheumatology, University Children's Hospital Basel, University of Basel, Basel, Switzerland.

Pokaż więcej

Źródło:

Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2024 Jan 02; Vol. 22 (1), pp. 5. Date of Electronic Publication: 2024 Jan 02.

Typ publikacji:

Journal Article

MeSH Terms:

Antirheumatic Agents*/adverse effects
Arthritis, Rheumatoid*/drug therapy
Female ; Humans ; Child ; Adalimumab/adverse effects ; Methotrexate/adverse effects ; Prospective Studies ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 30.

Tytuł:

Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus.

Autorzy:

Han JH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Joung KH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Division of Endocrinology and Metabolism, Department of International Medicine, Chungnam National University Sejong Hospital, Sejong, Korea.
Lee JC; Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea.
Kim OS; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Choung S; Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Korea.
Kim JM; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Division of Endocrinology and Metabolism, Department of International Medicine, Chungnam National University Sejong Hospital, Sejong, Korea.
Kang YE; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Yi HS; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Laboratory of Endocrinology and Immune System, Chungnam National University College of Medicine, Daejeon, Korea.
Lee JH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Ku BJ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Kim HJ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.

Pokaż więcej

Źródło:

Diabetes & metabolism journal [Diabetes Metab J] 2024 Jan; Vol. 48 (1), pp. 112-121. Date of Electronic Publication: 2024 Jan 03.

Typ publikacji:

Comparative Study; Journal Article; Randomized Controlled Trial

MeSH Terms:

Anticholesteremic Agents*/therapeutic use
Diabetes Mellitus, Type 2*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Insulin Resistance*
Humans ; Cholesterol, LDL ; Drug Therapy, Combination ; Ezetimibe/therapeutic use ; Rosuvastatin Calcium/therapeutic use ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 31.

Tytuł:

Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.

Autorzy:

Oh CK; Department of Internal Medicine, Gangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeoungdeungpo-gu, Seoul, 07441, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Lim H; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, 22 Gwanpyeong-ro 170-gil, Dongan-gu, Anyang, 14068, Korea. .; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea. .
Seo SI; Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150 Seongan-ro, Gangdong-gu, Seoul, 05355, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Lee SP; Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, 7 Keunjaebong-gil, Hwaseong, 18450, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Bang CS; Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, 77 Sakju-ro, Chuncheon, 24253, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Shin WG; Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150 Seongan-ro, Gangdong-gu, Seoul, 05355, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Kim JB; Department of Internal Medicine, Gangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeoungdeungpo-gu, Seoul, 07441, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Jang HJ; Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, 7 Keunjaebong-gil, Hwaseong, 18450, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Baik GH; Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, 77 Sakju-ro, Chuncheon, 24253, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.

Pokaż więcej

Źródło:

BMC gastroenterology [BMC Gastroenterol] 2023 Dec 21; Vol. 23 (1), pp. 453. Date of Electronic Publication: 2023 Dec 21.

Typ publikacji:

Clinical Trial Protocol; Journal Article

MeSH Terms:

Helicobacter Infections*/drug therapy
Helicobacter pylori*
Humans ; Amoxicillin/therapeutic use ; Amoxicillin/adverse effects ; Anti-Bacterial Agents/adverse effects ; Bismuth/therapeutic use ; Drug Therapy, Combination ; Metronidazole/therapeutic use ; Multicenter Studies as Topic ; Proton Pump Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Research Design

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 32.

Tytuł:

Combination Drug Therapy for the Management of Chronic Neuropathic Pain.

Autorzy:

Boccella S; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via De Amicis, 80131 Naples, Italy.
De Filippis L; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, Italy.
Giorgio C; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via De Amicis, 80131 Naples, Italy.
Brandolini L; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via Campo di Pile, 67100 L'Aquila, Italy.
Jones M; Research & Early Development (R&D), Dompé US, 181 2nd Avenue, STE 600, San Mateo, CA 94401, USA.
Novelli R; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, Italy.
Amorizzo E; Pain Unit, San Paolo Hospital, 00053 Civitavecchia, Italy.; Pain Clinic Roma, 00191 Rome, Italy.
Leoni MLG; Azienda USL di Piacenza, 29121 Piacenza, Italy.; Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University, 00185 Rome, Italy.
Terranova G; Pain Unit, ASST Gaetano Pini, 20122 Milan, Italy.
Maione S; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', 80138 Naples, Italy.
Luongo L; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', 80138 Naples, Italy.
Leone M; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, Italy.
Allegretti M; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via Campo di Pile, 67100 L'Aquila, Italy.
Minnella EM; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, Italy.
Aramini A; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via Campo di Pile, 67100 L'Aquila, Italy.

Pokaż więcej

Źródło:

Biomolecules [Biomolecules] 2023 Dec 16; Vol. 13 (12). Date of Electronic Publication: 2023 Dec 16.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Neuralgia*/drug therapy
Humans ; Drug Therapy, Combination ; Combined Modality Therapy

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 33.

Tytuł:

BMC3PM: bioinformatics multidrug combination protocol for personalized precision medicine and its application in cancer treatment.

Autorzy:

Mokhtari M; Department of Bioinformatics, Kish International Campus, University of Tehran, Kish Island, Iran. .
Khoshbakht S; Department of Bioinformatics, Kish International Campus, University of Tehran, Kish Island, Iran.; Duke Molecular Physiology Institute, Duke University School of Medicine-Cardiology, Durham, NC, 27701, USA.
Akbari ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Moravveji SS; Department of Bioinformatics, Kish International Campus, University of Tehran, Kish Island, Iran.

Pokaż więcej

Źródło:

BMC medical genomics [BMC Med Genomics] 2023 Dec 12; Vol. 16 (1), pp. 328. Date of Electronic Publication: 2023 Dec 12.

Typ publikacji:

Journal Article

MeSH Terms:

Precision Medicine*/methods
Neoplasms*/drug therapy
Neoplasms*/genetics
Humans ; Computational Biology ; Drug Therapy, Combination ; Drug Combinations

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 34.

Tytuł:

Sex differences in antiplatelet therapy: state-of-the art.

Autorzy:

Gasecka A; 1st Chair and Department of Cardiology, Medical University of Warsaw, Independent Public Central Teaching Hospital, Warsaw, Poland.
Zimodro JM; 1st Chair and Department of Cardiology, Medical University of Warsaw, Independent Public Central Teaching Hospital, Warsaw, Poland.
Appelman Y; Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, VU University, Amsterdam, The Netherlands.

Pokaż więcej

Źródło:

Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2176173. Date of Electronic Publication: 2023 Feb 21.

Typ publikacji:

Review; Journal Article

MeSH Terms:

Percutaneous Coronary Intervention*
Acute Coronary Syndrome*/drug therapy
Female ; Humans ; Male ; Platelet Aggregation Inhibitors/pharmacology ; Platelet Aggregation Inhibitors/therapeutic use ; Sex Factors ; Sex Characteristics ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Drug Therapy, Combination ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 35.

Tytuł:

Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial).

Autorzy:

Aumpan N; Center of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Thammasat University, Pathumthani, Thailand.; Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University, Pathumthani, Thailand.
Issariyakulkarn N; Center of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Thammasat University, Pathumthani, Thailand.
Mahachai V; Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University, Pathumthani, Thailand.
Graham D; Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America.
Yamaoka Y; Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America.; Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Yufu, Japan.; Research Center for Global and Local Infectious Diseases, Oita University, Yufu, Japan.
Vilaichone RK; Center of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Thammasat University, Pathumthani, Thailand.; Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University, Pathumthani, Thailand.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2023 Nov 30; Vol. 18 (11), pp. e0294403. Date of Electronic Publication: 2023 Nov 30 (Print Publication: 2023).

Typ publikacji:

Clinical Trial; Journal Article

MeSH Terms:

Helicobacter Infections*/drug therapy
Helicobacter Infections*/diagnosis
Helicobacter pylori*
Female ; Humans ; Male ; Middle Aged ; Amoxicillin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Clarithromycin/therapeutic use ; Drug Therapy, Combination ; Levofloxacin/therapeutic use ; Metronidazole/therapeutic use ; Retrospective Studies ; Treatment Failure

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 36.

Tytuł:

Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn's disease in Europe: a retrospective observational study.

Autorzy:

Weisshof R; Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel.
Vavricka SR; Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.; Center for Gastroenterology and Hepatology AG, Zürich, Switzerland.
Pouillon L; Department of Gastroenterology and Hepatology, Imelda GI Clinical Research Center, Imeldaziekenhuis Bonheiden, Belgium.
Braegger F; EUCAN Evidence Generation, Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Zürich, Switzerland.
Roset M; IQVIA, Real World Solutions, Barcelona, Spain.
Bent-Ennakhil N; EUCAN Evidence Generation, Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Zürich, Switzerland.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. .

Pokaż więcej

Źródło:

BMC gastroenterology [BMC Gastroenterol] 2023 Nov 29; Vol. 23 (1), pp. 417. Date of Electronic Publication: 2023 Nov 29.

Typ publikacji:

Observational Study; Journal Article

MeSH Terms:

Antibodies, Monoclonal, Humanized*/adverse effects
Crohn Disease*/drug therapy
Adult ; Humans ; Budesonide/therapeutic use ; Diarrhea/chemically induced ; Europe ; Gastrointestinal Agents/adverse effects ; Prospective Studies ; Remission Induction ; Retrospective Studies ; Treatment Outcome ; Drug Therapy, Combination/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 37.

Tytuł:

Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.

Autorzy:

Kontoghiorghes GJ; Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2023 Nov 25; Vol. 24 (23). Date of Electronic Publication: 2023 Nov 25.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Iron Overload*/etiology
Iron Overload*/chemically induced
beta-Thalassemia*/drug therapy
beta-Thalassemia*/complications
Humans ; Deferiprone/therapeutic use ; Deferoxamine/therapeutic use ; Pyridones/adverse effects ; Iron Chelating Agents/adverse effects ; Chelation Therapy/methods ; Iron/metabolism ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 38.

Tytuł:

Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis.

Autorzy:

Kim BG; Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
Lee SJ; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Lee YJ; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
You SC; Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.
Hong SJ; Korea University College of Medicine, Seoul, Korea.
Yun KH; Wonkwang University Hospital, Iksan, Korea.
Hong BK; Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Heo JH; Kosin University College of Medicine, Busan, Korea.
Rha SW; Korea University Guro Hospital, Seoul, Korea.
Hong SJ; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Ahn CM; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Kim BK; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Ko YG; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Choi D; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Hong MK; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea.
Jang Y; CHA Bundang Medical Center, CHA University College of Medicine, Seongnam, Korea.
Cho YH; Division of Cardiology, Myongji Hospital, Hwasu-ro 14-55, Deogyang-gu, Goyang, 10475, Gyeonggi-do, Korea. .
Kim JS; Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, 03722, Korea. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2023 Nov 17; Vol. 13 (1), pp. 20157. Date of Electronic Publication: 2023 Nov 17.

Typ publikacji:

Journal Article

MeSH Terms:

Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Anticholesteremic Agents*
Atherosclerosis*/drug therapy
Atherosclerosis*/chemically induced
Humans ; Female ; Male ; Ezetimibe/therapeutic use ; Rosuvastatin Calcium ; Cholesterol, LDL ; Drug Therapy, Combination ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 39.

Tytuł:

Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations.

Autorzy:

Alsohaibani F; Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
Peedikayil M; Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
Alshahrani A; Department of Medicine, Najran University, Najran, Kingdom of Saudi Arabia.
Somily A; Department of Pathology and Laboratory Medicine, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia.
Alsulaiman R; Department of Medicine, King Fahad Hospital, Imam Abdulrahman bin Faisal University, Dammam, Kingdom of Saudi Arabia.
Azzam N; Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Almadi M; Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Kingdom of Saudi Arabia; Division of Gastroenterology, McGill University Health Center, Montreal General Hospital, Montreal, QC, Canada.

Pokaż więcej

Źródło:

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2023 Nov-Dec; Vol. 29 (6), pp. 326-346.

Typ publikacji:

Journal Article

MeSH Terms:

Anti-Bacterial Agents*/therapeutic use
Helicobacter Infections*/drug therapy
Helicobacter Infections*/epidemiology
Helicobacter pylori*/drug effects
Humans ; Amoxicillin ; Bismuth/therapeutic use ; Drug Therapy, Combination ; Proton Pump Inhibitors ; Saudi Arabia/epidemiology

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 40.

Tytuł:

Unlocking the path to efficient H. pylori eradication: Embracing potassium-competitive acid blockers (P-CABs).

Autorzy:

Borody TJ; Department of Gastroenterology, The Centre for Digestive Diseases (CDD), Sydney, NSW, Australia.
Ng J; Axent Medical Pty Ltd., Sydney, NSW, Australia.
Dolai S; Department of Gastroenterology, The Centre for Digestive Diseases (CDD); Axent Medical Pty Ltd., Sydney, NSW, Australia.

Pokaż więcej

Źródło:

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2023 Nov-Dec; Vol. 29 (6), pp. 323-325.

Typ publikacji:

Editorial

MeSH Terms:

Helicobacter Infections*/drug therapy
Helicobacter Infections*/epidemiology
Helicobacter pylori*/drug effects
Humans ; Amoxicillin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Clarithromycin/therapeutic use ; Drug Therapy, Combination ; Potassium ; Proton Pump Inhibitors/therapeutic use ; Treatment Outcome

Opinia redakcyjna

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 41.

Tytuł:

Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials.

Autorzy:

Zhou BG; Dalian Medical University, Dalian, Liaoning Province; Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China.
Mei YZ; Department of Gastroenterology, The People's Hospital of China Three Gorges University, Yichang, Hubei Province, China.
Jiang X; Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China.
Zheng AJ; Department of Gastroenterology, The People's Hospital of China Three Gorges University, Yichang, Hubei Province, China.
Ding YB; Dalian Medical University, Dalian, Liaoning Province; Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China.

Pokaż więcej

Źródło:

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2023 Nov-Dec; Vol. 29 (6), pp. 347-357.

Typ publikacji:

Meta-Analysis; Systematic Review; Journal Article

MeSH Terms:

Helicobacter pylori*
Helicobacter Infections*/drug therapy
Humans ; Amoxicillin/therapeutic use ; Amoxicillin/pharmacology ; Clarithromycin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Proton Pump Inhibitors ; Randomized Controlled Trials as Topic ; Drug Therapy, Combination ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 42.

Tytuł:

Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients.

Autorzy:

Jain N; Department of Medicine, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
Garg R; Department of Medicine, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
Singh GP; Department of Community Medicine, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
Kaur S; Department of Medicine, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
Chawla SPS; Department of Medicine, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
Padda P; Department of Community Medicine, Government Medical College, Amritsar, Punjab, India.

Pokaż więcej

Źródło:

Annals of African medicine [Ann Afr Med] 2023 Oct-Dec; Vol. 22 (4), pp. 456-464.

Typ publikacji:

Observational Study; Journal Article

MeSH Terms:

Coinfection*/drug therapy
Coinfection*/complications
Hepatitis C*
Hepatitis C, Chronic*/drug therapy
Hepatitis C, Chronic*/epidemiology
Hepatitis C, Chronic*/complications
HIV Infections*/drug therapy
Substance-Related Disorders*/complications
Substance-Related Disorders*/drug therapy
Thrombocytopenia*/complications
Thrombocytopenia*/drug therapy
Adult ; Female ; Humans ; Male ; Middle Aged ; Antiviral Agents/therapeutic use ; Drug Therapy, Combination ; Hepacivirus/genetics ; Liver Cirrhosis/complications ; Liver Cirrhosis/drug therapy ; Transaminases ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 43.

Tytuł:

Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework.

Autorzy:

Chen CY; Institute of Public Health, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Pan SW; Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Hsu CC; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan.
Liu JJ; Institute of Public Health, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Kumamaru H; Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Dong YH; Institute of Public Health, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. .; Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. .; Institute of Hospital and Health Care Administration, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. .

Pokaż więcej

Źródło:

Respiratory research [Respir Res] 2023 Sep 29; Vol. 24 (1), pp. 239. Date of Electronic Publication: 2023 Sep 29.

Typ publikacji:

Journal Article

MeSH Terms:

Heart Failure*/drug therapy
Ischemic Stroke*/chemically induced
Ischemic Stroke*/drug therapy
Myocardial Infarction*/diagnosis
Myocardial Infarction*/drug therapy
Myocardial Infarction*/epidemiology
Pulmonary Disease, Chronic Obstructive*/diagnosis
Pulmonary Disease, Chronic Obstructive*/drug therapy
Pulmonary Disease, Chronic Obstructive*/epidemiology
Humans ; Administration, Inhalation ; Adrenal Cortex Hormones/adverse effects ; Angina, Unstable/chemically induced ; Angina, Unstable/drug therapy ; Arrhythmias, Cardiac/chemically induced ; Arrhythmias, Cardiac/drug therapy ; Bronchodilator Agents/adverse effects ; Cohort Studies ; Drug Therapy, Combination ; Muscarinic Antagonists/adverse effects ; Clinical Trials as Topic

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 44.

Tytuł:

Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis.

Autorzy:

Li M; Department of Neurology, Xi'an International Medical Center Hospital, Xitai Road, Gaoxin District, Xi'an City, 710010, Shaanxi Province, China.
Yang Q; Department of Neurology, Xi'an International Medical Center Hospital, Xitai Road, Gaoxin District, Xi'an City, 710010, Shaanxi Province, China.
Shi J; Department of Neurology, Xi'an International Medical Center Hospital, Xitai Road, Gaoxin District, Xi'an City, 710010, Shaanxi Province, China.
Zhang X; Department of Neurology, Xi'an International Medical Center Hospital, Xitai Road, Gaoxin District, Xi'an City, 710010, Shaanxi Province, China.
Lin H; Department of Neurology, Xi'an International Medical Center Hospital, Xitai Road, Gaoxin District, Xi'an City, 710010, Shaanxi Province, China. .
Ge F; Department of Neurology, Xi'an International Medical Center Hospital, Xitai Road, Gaoxin District, Xi'an City, 710010, Shaanxi Province, China. .

Pokaż więcej

Źródło:

BMC neurology [BMC Neurol] 2023 Aug 14; Vol. 23 (1), pp. 303. Date of Electronic Publication: 2023 Aug 14.

Typ publikacji:

Meta-Analysis; Journal Article

MeSH Terms:

Ischemic Attack, Transient*/drug therapy
Ischemic Attack, Transient*/prevention & control
Stroke*/drug therapy
Stroke*/prevention & control
Ischemic Stroke*/drug therapy
Ischemic Stroke*/prevention & control
Humans ; Aspirin/therapeutic use ; Platelet Aggregation Inhibitors/therapeutic use ; Ticagrelor/therapeutic use ; Clopidogrel/therapeutic use ; Network Meta-Analysis ; Drug Therapy, Combination ; Hemorrhage/drug therapy

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 45.

Tytuł:

Direct-Acting Antiviral Drug Modulates the Mitochondrial Biogenesis in Different Tissues of Young Female Rats.

Autorzy:

Hafez HA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Atoom AM; Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19111, Jordan.
Khafaga RHM; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Shaker SA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Kamel MA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Assem NM; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.
Mahmoud SA; Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria 21561, Egypt.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2023 Oct 31; Vol. 24 (21). Date of Electronic Publication: 2023 Oct 31.

Typ publikacji:

Journal Article

MeSH Terms:

Hepatitis C, Chronic*/drug therapy
Hepatitis C*/drug therapy
Female ; Rats ; Animals ; Antiviral Agents ; Organelle Biogenesis ; Treatment Outcome ; Rats, Wistar ; Sofosbuvir/therapeutic use ; Hepacivirus/genetics ; Drug Therapy, Combination ; Genotype

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 46.

Tytuł:

Exploring the feasibility of introducing triple artemisinin-based combination therapy in the malaria treatment policy in Vietnam.

Autorzy:

Cao VAT; The University of North Carolina Project Office, Hanoi, Vietnam. .
Nguyen TQ; National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam.
Le Quyen D; World Mosquito Program, Ho Chi Minh, Vietnam.
Boon WPC; Copernicus Institute of Sustainable Development, Utrecht University, Utrecht, The Netherlands.
Moors EHM; Copernicus Institute of Sustainable Development, Utrecht University, Utrecht, The Netherlands.
Dondorp AM; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
de Haan F; Copernicus Institute of Sustainable Development, Utrecht University, Utrecht, The Netherlands.
Amaratunga C; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Pokaż więcej

Źródło:

Malaria journal [Malar J] 2023 Oct 28; Vol. 22 (1), pp. 326. Date of Electronic Publication: 2023 Oct 28.

Typ publikacji:

Review; Journal Article

MeSH Terms:

Antimalarials*/therapeutic use
Malaria, Falciparum*/drug therapy
Artemisinins*/therapeutic use
Malaria*/drug therapy
Malaria*/prevention & control
Humans ; Vietnam ; Feasibility Studies ; Plasmodium falciparum ; Drug Therapy, Combination ; Policy

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 47.

Tytuł:

Comparison of the management of Helicobacter pylori infection between the older and younger European populations.

Autorzy:

Jonaitis P; Department of Gastroenterology, Lithuanian University of Health Sciences, 50161, Kaunas, Lithuania.
Nyssen OP; Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad Autónoma de Madrid (UAM), Diego de León, 62, 28006, Madrid, Spain. .
Saracino IM; Department of Surgical and Medical Sciences, IRCCS AOUBO, University of Bologna, 40138, Bologna, Italy.
Fiorini G; Department of Surgical and Medical Sciences, IRCCS AOUBO, University of Bologna, 40138, Bologna, Italy.
Vaira D; Department of Surgical and Medical Sciences, IRCCS AOUBO, University of Bologna, 40138, Bologna, Italy.
Pérez-Aísa Á; Agencia Sanitaria Costa del Sol, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), 29651, Marbella, Spain.
Tepes B; Department of Gastroenterology, AM DC Rogaska, 3250, Rogaska Slatina, Slovenia.
Castro-Fernandez M; Department of Gastroenterology, Hospital de Valme, 41014, Seville, Spain.
Pabón-Carrasco M; Department of Gastroenterology, Hospital de Valme, 41014, Seville, Spain.
Keco-Huerga A; Department of Gastroenterology, Hospital de Valme, 41014, Seville, Spain.
Voynovan I; Department of Gastroenterology, A.S. Loginov Moscow Clinical Scientific Center, 111123, Moscow, Russia.
Lucendo AJ; Department of Gastroenterology, Hospital General de Tomelloso, 13700, Tomelloso, Spain.
Lanas Á; IIS Aragón y Facultad de Medicina de la Universidad de Zaragoza, 50009, Zaragoza, Spain.
Martínez-Domínguez SJ; IIS Aragón y Facultad de Medicina de la Universidad de Zaragoza, 50009, Zaragoza, Spain.
Almajano EA; IIS Aragón y Facultad de Medicina de la Universidad de Zaragoza, 50009, Zaragoza, Spain.
Rodrigo L; Gastroenterology Unit, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain.
Vologzanina L; Department of Gastroenterology, Gastrocentre, 614068, Perm, Russia.
Brglez Jurecic N; Department of Gastroenterology, Interni Oddelek, Diagnostic Centre, 4260, Bled, Slovenia.
Denkovski M; Department of Gastroenterology, Interni Oddelek, Diagnostic Centre, 4260, Bled, Slovenia.
Bujanda L; Hospital Donostia, Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), 20018, San Sebastián, Spain.
Mahmudov U; Modern Hospital, 1119, Baku, Azerbaijan.
Leja M; Department of Gastroenterology, Digestive Diseases Centre Gastro, Institute of Clinical and Preventive Medicine and Faculty of Medicine, University of Latvia, Riga, 1079, Latvia.
Lerang F; Department of Gastroenterology, Østfold Hospital Trust, 1714, Grålum, Norway.
Babayeva G; Memorial Klinik, 1096, Baku, Azerbaijan.
Bordin DS; Department of Gastroenterology, A.S. Loginov Moscow Clinical Scientific Center, 111123, Moscow, Russia.; A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 127473, Moscow, Russia.; Tver State Medical University, 170100, Tver, Russia.
Gasbarrini A; Medicina Interna, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Kupcinskas J; Department of Gastroenterology, Lithuanian University of Health Sciences, 50161, Kaunas, Lithuania.
Gridnyev O; Government Institution 'L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine', Kyiv, Ukraine.
Rokkas T; Department of Gastroenterology, Henry Dunant Hospital, 115 26, Athens, Greece.
Marcos-Pinto R; Department of Gastroenterology, Centro Hospitalar do Porto Institute of Biomedical Sciences Abel Salazar, Centro de Investigação em Tecnologias e Serviços de Saúde, University of Porto, 4050-313, Porto, Portugal.
Phull PS; Department of Gastroenterology, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, UK.
Smith SM; Faculty of Health Sciences, Trinity College Dublin, Dublin, D02PN40, Ireland.
Tonkić A; Department of Gastroenterology, University Hospital of Split, University of Split School of Medicine, 21000, Split, Croatia.
Boltin D; Division of Gastroenterology, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, 49100, Tel Aviv, Israel.
Buzás GM; Department of Gastroenterology, Ferencváros Health Centre, 1095, Budapest, Hungary.
Šembera Š; 2nd Department of Internal Medicine and Gastroenterology, University Hospital and Charles University, Faculty of Medicine in Hradec Králové, 500 03, Hradec Králové, Czech Republic.
Şimşek H; Division of Gastroenterology and Hepatology, Hacettepe University School of Medicine, 06230, Ankara, Turkey.
Matysiak-Budnik T; Department of Gastroenterology, CHRU de Nantes, Hôpital Hôtel Dieu, 44000, Nantes, France.
Milivojevic V; Department of Gastroenterology, Clinical Center of Serbia, University of Belgrade School of Medicine, 11000, Belgrade, Serbia.
Marlicz W; Department of Gastroenterology, Pomeranian Medical University, 70-204, Szczecin, Poland.
Venerito M; Department of Gastroenterology, Otto-Von-Guericke University, 39120, Magdeburg, Germany.
Boyanova L; Department of Gastroenterology, Medical Microbiology, Medical University of Sofia, 1431, Sofia, Bulgaria.
Doulberis M; Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, 5001, Aarau, Switzerland.
Capelle LG; Department of Gastroenterology, Meander Medical Center, 3813 TZ, Amersfoort, The Netherlands.
Cano-Català A; GOES Research Group, Althaia Xarxa Assistencial Universitària de Manresa, 08243, Manresa, Spain.
Moreira L; Department of Gastroenterology, Hospital Clínic Barcelona, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), University of Barcelona, 08036, Barcelona, Spain.
Mégraud F; INSERM U1312, Université de Bordeaux, 33000, Bordeaux, France.
O'Morain C; Faculty of Health Sciences, Trinity College Dublin, Dublin, D02PN40, Ireland.
Gisbert JP; Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad Autónoma de Madrid (UAM), Diego de León, 62, 28006, Madrid, Spain.
Jonaitis L; Department of Gastroenterology, Lithuanian University of Health Sciences, 50161, Kaunas, Lithuania.

Pokaż więcej

Corporate Authors:

Hp-EuReg investigators

Źródło:

Scientific reports [Sci Rep] 2023 Oct 11; Vol. 13 (1), pp. 17235. Date of Electronic Publication: 2023 Oct 11.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Helicobacter Infections*/drug therapy
Helicobacter Infections*/epidemiology
Helicobacter pylori*
Hypersensitivity*/drug therapy
Humans ; Aged ; Anti-Bacterial Agents/adverse effects ; Bismuth/therapeutic use ; Drug Therapy, Combination ; Proton Pump Inhibitors/adverse effects ; Penicillins/therapeutic use ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 48.

Tytuł:

A novel noble metal stent coating reduces in vitro platelet activation and acute in vivo thrombosis formation: a blinded study.

Autorzy:

Sandell M; Division of Micro and Nanosystems, KTH Royal Institute of Technology, Malvinas väg 10, 114 28, Stockholm, Sweden.; Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 77, Stockholm, Sweden.; MedTechLabs, Stockholm, Sweden.
Ericsson A; Bactiguard AB, Alfred Nobels allé 150, 146 48, Tullinge, Sweden.
Al-Saadi J; Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 77, Stockholm, Sweden.
Södervall B; Bactiguard AB, Alfred Nobels allé 150, 146 48, Tullinge, Sweden.
Södergren E; Bactiguard AB, Alfred Nobels allé 150, 146 48, Tullinge, Sweden.
Grass S; Bactiguard AB, Alfred Nobels allé 150, 146 48, Tullinge, Sweden.
Sanchez J; Bactiguard AB, Alfred Nobels allé 150, 146 48, Tullinge, Sweden.; Department of Clinical Sciences, Danderyd Hospital, 182 88, Stockholm, Sweden.
Holmin S; Department of Clinical Neuroscience, Karolinska Institute, Tomtebodavägen 18A, 171 77, Stockholm, Sweden. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2023 Oct 11; Vol. 13 (1), pp. 17225. Date of Electronic Publication: 2023 Oct 11.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Coronary Artery Disease*/drug therapy
Drug-Eluting Stents*
Thrombosis*/drug therapy
Percutaneous Coronary Intervention*
Humans ; Animals ; Swine ; Platelet Aggregation Inhibitors/pharmacology ; Platelet Aggregation Inhibitors/therapeutic use ; Stents/adverse effects ; Platelet Activation ; Treatment Outcome ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 49.

Tytuł:

Efficacy and safety of montelukast adjuvant therapy in adults with cough variant asthma: A systematic review and meta-analysis.

Autorzy:

Xu Q; Clinical College of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.; Institute of Clinical Research and Evidence-Based Medicine, Gansu Provincial Hospital, Lanzhou, Gansu, China.; Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China.
Lu T; Institute of Clinical Research and Evidence-Based Medicine, Gansu Provincial Hospital, Lanzhou, Gansu, China.; Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China.
Song Z; Gansu Provincial Cancer Clinical Research Center of Integrated Traditional Chinese and Western Medicine, Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Zhu P; Clinical College of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Wu Y; Clinical College of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Zhang L; Clinical College of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Yang K; Institute of Clinical Research and Evidence-Based Medicine, Gansu Provincial Hospital, Lanzhou, Gansu, China.; Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China.
Zhang Z; Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, Gansu, China.

Pokaż więcej

Źródło:

The clinical respiratory journal [Clin Respir J] 2023 Oct; Vol. 17 (10), pp. 986-997. Date of Electronic Publication: 2023 May 22.

Typ publikacji:

Meta-Analysis; Systematic Review; Journal Article; Review

MeSH Terms:

Anti-Asthmatic Agents*/adverse effects
Asthma*/drug therapy
Adult ; Humans ; Cough/drug therapy ; Cough/chemically induced ; Adrenergic beta-Agonists ; Drug Therapy, Combination ; Adrenal Cortex Hormones/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 50.

Tytuł:

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.

Autorzy:

Flamm S; Department of Internal Medicine, Division of Digestive Diseases and Nutrition, Rush University Medical Center, Chicago, IL 60612, USA.
Lawitz E; Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX 78215, USA.
Borg B; Southern Therapy and Advanced Research LLC, Jackson, MS 39216, USA.
Charlton M; Intermountain Medical Center, Murray, UT 84107, USA.
Landis C; Division of Gastroenterology and Hepatology, University of Washington, Seattle, WA 98101, USA.
Reddy KR; Department of Medicine, Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Shiffman M; Bon Secours Mercy Health, Liver Institute of Virginia, Richmond, VA 23226, USA.
Alsina A; Tampa General Medical Group, Tampa, FL 33609, USA.
Chang C; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ravendhran N; Digestive Disease Associates, Catonsville, MD 21228, USA.
Hernandez C; Gilead Sciences, Inc., Foster City, CA 94404, USA.
Hézode C; Gilead Sciences, Inc., Foster City, CA 94404, USA.
Scherbakovsky S; Gilead Sciences, Inc., Foster City, CA 94404, USA.
Mercier RC; Gilead Sciences, Inc., Foster City, CA 94404, USA.
Samuel D; Centre Hépatobiliaire, Hôpital Paul-Brousse, Inserm Research Unit 1193, Université Paris-Saclay, 94800 Villejuif, France.

Pokaż więcej

Źródło:

Viruses [Viruses] 2023 Sep 29; Vol. 15 (10). Date of Electronic Publication: 2023 Sep 29.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Hepatitis C*/drug therapy
Hepatitis C, Chronic*/complications
Hepatitis C, Chronic*/drug therapy
Adult ; Humans ; Sofosbuvir/adverse effects ; Ribavirin/adverse effects ; Hepacivirus/genetics ; Antiviral Agents/adverse effects ; Treatment Outcome ; Genotype ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły